Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase

Hao Huang, Guangyuan Zhao, Horacio Cardenas, Andres Felipe Valdivia, Yinu Wang, Daniela Matei

Mol Cancer Ther (2023) 22 (3): 393–405.

https://doi.org/10.1158/1535-7163.MCT-22-0278

Published: 02 March 2023

View article titled, N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase

Includes: Supplementary data

Journal Articles

Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Livia Elena Sima, Bakhtiyor Yakubov, Sheng Zhang, Salvatore Condello, Arabela A. Grigorescu, Nkechiyere G. Nwani, Lan Chen, Gary E. Schiltz, Constandina Arvanitis, Zhong-Yin Zhang, Daniela Matei

Mol Cancer Ther (2019) 18 (6): 1057–1068.

https://doi.org/10.1158/1535-7163.MCT-18-1148

Published: 03 June 2019

View article titled, Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Includes: Supplementary data

Journal Articles

Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.

Ron L. Korn, Michael S. Gordon, Lee S. Rosen, Francisco Robert, Daniela Matei, Jonathan W. Goldman, David S. Mendelson, E. Gabriela Chiorean, Robert Matthew Strother, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer

Mol Cancer Ther (2013) 12 (11_Supplement): A2.

https://doi.org/10.1158/1535-7163.TARG-13-A2

Published: 01 November 2013

View article titled, Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.

Journal Articles

Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer

Minghai Shao, Stacy Hollar, Daphne Chambliss, Jordan Schmitt, Robert Emerson, Bhadrani Chelladurai, Susan Perkins, Mircea Ivan, Daniela Matei

Mol Cancer Ther (2012) 11 (7): 1576–1586.

https://doi.org/10.1158/1535-7163.MCT-11-0961

Published: 05 July 2012

View article titled, Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer

Includes: Supplementary data

Journal Articles

Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase

May Khanna, Bhadrani Chelladurai, Aruna Gavini, Liwei Li, Minghai Shao, David Courtney, John J. Turchi, Daniela Matei, Samy Meroueh

Mol Cancer Ther (2011) 10 (4): 626–636.

https://doi.org/10.1158/1535-7163.MCT-10-0912

Published: 06 April 2011

View article titled, Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase

Journal Articles

Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem^® NCD administered orally to patients with ovarian cancer

Daniela Matei, Jeanne Schilder, Nancy Menning, Jamie Arnott, Gregory Sutton, Karuna Koneru, Carolyn Sidor

Mol Cancer Ther (2007) 6 (11_Supplement): A14.

Published: 01 November 2007

View article titled, Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem<sup>®</sup> NCD administered orally to patients with ovarian cancer

NARROW

N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase

Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.

Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer

Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase

Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem^® NCD administered orally to patients with ovarian cancer

Email alerts

AACR Journals

N6-Methyladenosine RNA Modifications Regulate the Response to Platinum Through Nicotinamide N-methyltransferase

Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

Abstract A2: Exploratory textural CT evaluation of the combination of TRC105 (anti-endoglin monoclonal antibody; MAb) and bevacizumab (BEV) indicates partial response by Choi criteria in BEV refractory advanced cancer patients (pts) and identifies candidate markers of response.

Targeting the Insulin Growth Factor and the Vascular Endothelial Growth Factor Pathways in Ovarian Cancer

Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase

Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem® NCD administered orally to patients with ovarian cancer

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem^® NCD administered orally to patients with ovarian cancer